A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.

Trial Details

NCT ID
NCT07069712
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Sonesitatug Vedotin
  • Rilvegostomig
  • Trastuzumab Deruxtecan (T-DXd)
  • Capecitabine
  • 5-Fluorouracil (5-FU)
  • FLOT Chemotherapy
Locations (sample)
  • Newark, Delaware, United States|39.68372,-75.74966
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Fairway, Kansas, United States|39.02223,-94.6319
  • North Shores, Michigan, United States|41.83643,-83.40743
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Histologically documented gastric, GEJ, or esophageal adenocarcinoma with resectable disease
  • Participants who are CLDN18.2-positive in Sub-study 1 or HER2-positive in Sub-study 2; no specific requirements for Sub-study 3
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ and bone marrow function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →